BioSpace News Archive

-- First highly effective treatment option approved in Europe for PDGFRA D842V mutant GIST -- -- 95% ORR and 22.1 month median DOR in patients with unresectable or metastatic PDGFRA D842V mutant GIST in the NAVIGATOR trial1 --

Medscape Education has been selected as a partner in hosting The Heart Failure Society of America Virtual Annual Scientific Meeting 2020, September 30-October 6.

Annual program recognizes rising leaders who are making strides in the field of managed care research

- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease - Company p lans to initiate Phase 1 trial in healthy volunteers by year-end - N on-provisional composition of matter patent application covering FTX-6058 published CAMBRIDGE, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving t

Schwazze, formerly operating as Medicine Man Technologies, Inc. (OTCQX: SHWZ) (“Schwazze” or “the Company”), announced today that Justin Dye, Chief Executive Officer, and Nancy Huber, Chief Financial Officer, will be hosting meetings at the Alliance Global Partners Virtual Consumer Cannabis Conference on Tuesday, September 29, 2020.

Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma Applied Research Foundation, Novocure has arranged for 25 buildings and landmarks to be lit in blue, the color associated with mesothelioma awareness. In 18 cities across the country including New York, Miami, Chicago, Dallas and Seattle, the illumination of these lo

Binovi Technologies Corp., wishes to congratulate the National Hockey League’s Dallas Stars on their Western Conference Championship and berth in the Stanley Cup Finals.

GoodRx Holdings Inc. , a leading consumer-focused digital healthcare platform in the United States, today announced the closing of its initial public offering of 39,807,691 shares of its Class A common stock at a price to the public of $33.00 per share. Of the offered shares, 28,615,034 shares were offered by GoodRx and 11,192,657 shares were offered by certain selling shareholders. The number of shares offered an

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or lon

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral,